UY33149A - Compuestos carboxamida y su uso como inhibidores iv de calpaina - Google Patents

Compuestos carboxamida y su uso como inhibidores iv de calpaina

Info

Publication number
UY33149A
UY33149A UY0001033149A UY33149A UY33149A UY 33149 A UY33149 A UY 33149A UY 0001033149 A UY0001033149 A UY 0001033149A UY 33149 A UY33149 A UY 33149A UY 33149 A UY33149 A UY 33149A
Authority
UY
Uruguay
Prior art keywords
alkyl
aryl
heteroaryl
carboxamide compounds
calpaina
Prior art date
Application number
UY0001033149A
Other languages
English (en)
Inventor
Kling Andreas
Jantos Katja
Mack Helmut
Achim Moeller
Hornberger Wilfried
Backfisch Gisela
Lao Yanbin
Nijsen Marjoleen
Original Assignee
Abbott Lab
Abbot Gmbh Y Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab, Abbot Gmbh Y Co Kg filed Critical Abbott Lab
Publication of UY33149A publication Critical patent/UY33149A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Compuestos carboxamida inhibidores de calpaína y uso para la elaboración de un medicamento para tra tar un trastorno asociado con actividad elevada d e calpaína. Son de fórmula I donde R1, R2, R3 R4, R5, m y n son de acuerdo con reivindicaciones y d escripción, sus tautómeros, hidratos y sales farmacéuticamente apropiados. Preferiblemente aquellos donde R1 es fenil-C1-C2-alquilo o hetaril-C1-C2-alquilo opcionalmente sustituido, R2 es arilo, hetarilo, aril-C1-C6-alquilo, aril-C2-C6-alquenilo o hetaril-C1-C4-alquilo opcionalmente sustituido, R3 es C3-C4-alquilo, C1-C4-haloalquilo, C2-C4-alquenilo, C3-C6-cicloalquilo, C3-C6-cicloalquil-C1-C2-alquilo, C3-C6-heterocicloalquil-C1-C2-alquilo, fenil-C1-C3-alquilo, piridin-2-il-C1-C3-alquilo o 1,3-benzoxazol-2-il-metilo, R4 y R5 son, de manera ind ependiente, halógeno, CF3, CHF2, CH2F, C1-C2-alquilo o C1-C2 -alcoxi, y m y n son, de manera independiente 0 ó 1.
UY0001033149A 2009-12-22 2010-12-22 Compuestos carboxamida y su uso como inhibidores iv de calpaina UY33149A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28891809P 2009-12-22 2009-12-22
US41047610P 2010-11-05 2010-11-05

Publications (1)

Publication Number Publication Date
UY33149A true UY33149A (es) 2011-06-30

Family

ID=43707825

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033149A UY33149A (es) 2009-12-22 2010-12-22 Compuestos carboxamida y su uso como inhibidores iv de calpaina

Country Status (11)

Country Link
US (2) US8598211B2 (es)
EP (1) EP2516415B1 (es)
JP (2) JP5913125B2 (es)
CN (2) CN105732581A (es)
AR (1) AR079665A1 (es)
CA (1) CA2783714A1 (es)
ES (1) ES2477583T3 (es)
MX (1) MX2012007322A (es)
TW (1) TW201132632A (es)
UY (1) UY33149A (es)
WO (1) WO2011076812A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236798B2 (en) 2009-05-07 2012-08-07 Abbott Gmbh & Co. Kg Carboxamide compounds and their use as calpain inhibitors
US8598211B2 (en) * 2009-12-22 2013-12-03 Abbvie Inc. Carboxamide compounds and their use as calpain inhibitors IV
WO2012076639A1 (en) * 2010-12-09 2012-06-14 Abbott Gmbh & Co. Kg Carboxamide compounds and their use as calpain inhibitors v
EP2834230A1 (en) * 2012-04-03 2015-02-11 AbbVie Deutschland GmbH & Co KG Carboxamide compounds and their use as calpain inhibitors v
WO2014089364A1 (en) 2012-12-06 2014-06-12 Quanticel Pharmaceuticals, Inc Histone demethylase inhibitors
WO2017156071A1 (en) 2016-03-09 2017-09-14 Blade Therapeutics, Inc. Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof
WO2018009417A1 (en) 2016-07-05 2018-01-11 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
KR20190063473A (ko) 2016-09-28 2019-06-07 블레이드 테라퓨틱스, 인크. 칼페인 조정자 및 그 치료학적 용도
WO2023165334A1 (zh) * 2022-03-01 2023-09-07 成都威斯克生物医药有限公司 酮酰胺类衍生物及其制药用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826835A (en) 1985-10-23 1989-05-02 Rorer Pharmaceutical Corporation Pyridyl-pyridazinone and pyridyl-pyrazolinone compounds and their use in the treatment of congestive heart failure
US4743608A (en) 1986-07-15 1988-05-10 Rorer Pharmaceutical Corporation Pyridone-pyridyl-imidazolyl and triazolyl compounds and their use as cardiotonic agents
DE19642591A1 (de) 1996-10-15 1998-04-16 Basf Ag Neue Piperidin-Ketocarbonsäure-Derivate, deren Herstellung und Anwendung
DE19650975A1 (de) * 1996-12-09 1998-06-10 Basf Ag Neue heterocyclisch substituierte Benzamide und deren Anwendung
ATE244216T1 (de) * 1996-12-11 2003-07-15 Abbott Gmbh & Co Kg Ketobenzamide als calpain-inhibitoren
US6083944A (en) 1997-10-07 2000-07-04 Cephalon, Inc. Quinoline-containing α-ketoamide cysteine and serine protease inhibitors
CN1306526A (zh) 1998-04-20 2001-08-01 Basf公司 具有半胱氨酸蛋白酶抑制作用的新的杂环取代酰胺
DE19818614A1 (de) * 1998-04-20 1999-10-21 Basf Ag Neue substituierte Amide, deren Herstellung und Anwendung
EP1073641B1 (de) 1998-04-20 2004-04-14 Abbott GmbH & Co. KG Neue substituierte amide, deren herstellung und anwendung
EP1082308B1 (de) 1998-04-20 2009-04-01 Abbott GmbH & Co. KG Heterocyclisch substituierte amide als calpainhemmer
DE19817459A1 (de) 1998-04-20 1999-10-21 Basf Ag Neue heterozyklische substituierte Amide, Herstellung und Anwendung
ATE344794T1 (de) 1998-05-25 2006-11-15 Abbott Gmbh & Co Kg Heterocyclische substituierte amide, deren herstellung und verwendung
DE10114762A1 (de) 2001-03-26 2002-10-02 Knoll Gmbh Verwendung von Cysteinprotease-Inhibitoren
MX2008001528A (es) 2005-08-02 2008-04-04 Vertex Pharma Inhibidores de serina proteasas.
ES2536626T3 (es) * 2006-12-29 2015-05-27 Abbvie Deutschland Gmbh & Co Kg Compuestos de carboxamida y su uso como inhibidores de calpaína
US8435984B2 (en) 2007-02-26 2013-05-07 Achillion Pharmaceuticals, Inc. Tertiary amine substituted peptides useful as inhibitors of HCV replication
TWI453019B (zh) * 2007-12-28 2014-09-21 Abbvie Deutschland 甲醯胺化合物
US8598211B2 (en) * 2009-12-22 2013-12-03 Abbvie Inc. Carboxamide compounds and their use as calpain inhibitors IV

Also Published As

Publication number Publication date
JP2016065071A (ja) 2016-04-28
ES2477583T3 (es) 2014-07-17
CN105732581A (zh) 2016-07-06
JP5913125B2 (ja) 2016-04-27
CA2783714A1 (en) 2011-06-30
TW201132632A (en) 2011-10-01
WO2011076812A1 (en) 2011-06-30
US20140179702A1 (en) 2014-06-26
JP2013515040A (ja) 2013-05-02
EP2516415B1 (en) 2014-04-09
CN102753541A (zh) 2012-10-24
US20110152325A1 (en) 2011-06-23
EP2516415A1 (en) 2012-10-31
AR079665A1 (es) 2012-02-08
MX2012007322A (es) 2012-11-06
US8598211B2 (en) 2013-12-03

Similar Documents

Publication Publication Date Title
UY33149A (es) Compuestos carboxamida y su uso como inhibidores iv de calpaina
UY33150A (es) Compuestos carboxamida y su uso como inhibidores v de calpaína
PH12016501972B1 (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
MX2014004307A (es) Inhibidores de proteinas quinasas.
EA201190158A1 (ru) Производные бензофуранила для применения в качестве ингибиторов глюкокиназы
MX2013004491A (es) Boronatos como inhibidores de arginasa.
ATE552255T1 (de) 4-aminoindazole
WO2016044641A3 (en) Carm1 inhibitors and uses thereof
MX338114B (es) Inhibidores de arginasa y sus aplicaciones terapeuticas.
MX2015012850A (es) Inhibidores de la arginina metiltransferasa y usos de los mismos.
NZ710405A (en) Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
JO3025B1 (ar) الأندازولات المستبدلة بالأوكسازول كمثبطات كيناز pi3
RS53617B1 (en) NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
MX355088B (es) Inhibidores de tienopirimidina de proteina cinasa c atipica.
UA108510C2 (en) Cyclopropane compound
PH12015501755A1 (en) Azabenzimidazole compounds as inhibitors of pde4 isozymes for the treatment of cns and other disorders
WO2010144499A3 (en) Urea derivatives as kinase inhibitors
MY170922A (en) Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
MX338551B (es) Nuevos compuestos de piridina fusionada como inhibidores de caseina quinasa.
MX368178B (es) Compuestos de ácido dimetilbenzoico.
PH12019500497A1 (en) Heteroaryl carboxamide compounds as inhibitors of ripk2
EA201490754A1 (ru) Производные карбамата/мочевины, содержащие пиперидиновые и пиперазиновые кольца, в качестве ингибиторов н3 рецептора
NZ605558A (en) Benzamide derivatives and their use as hsp90 inhibitors
MX2017005422A (es) Inhibidores de histona desacetilasa y sus usos en terapia.
EA201491227A1 (ru) Новые производные морфолинила, подходящие для применения в качестве ингибиторов mogat-2

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20190521